Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Stock Short Interest Climbs 200.8%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a significant increase in short interest during the month of October. As of October 30th, there was short interest totaling 47,382 shares, an increase of 200.8% from the October 15th total of 15,751 shares. Based on an average daily trading volume, of 1,264,801 shares, the short-interest ratio is presently 0.0 days. Currently, 2.7% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Thursday, October 15th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $14.50.

Bolt Biotherapeutics Stock Up 2.9%

BOLT traded up $0.17 during trading on Friday, hitting $6.08. The company had a trading volume of 28,108 shares, compared to its average volume of 746,433. The company has a market capitalization of $11.73 million, a PE ratio of -0.41 and a beta of 0.85. Bolt Biotherapeutics has a one year low of $3.10 and a one year high of $7.78. The firm’s 50-day moving average price is $4.63 and its 200 day moving average price is $4.51. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 1.47.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its earnings results on Thursday, November 12th. The company reported ($2.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.68) by $1.43. The firm had revenue of $0.45 million during the quarter, compared to analysts’ expectations of $0.45 million. Bolt Biotherapeutics had a negative return on equity of 132.36% and a negative net margin of 611.47%. As a group, equities analysts expect that Bolt Biotherapeutics will post -11.10 earnings per share for the current year.

Insider Transactions at Bolt Biotherapeutics

In other news, major shareholder Coastlands Capital Lp purchased 50,000 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The shares were acquired at an average cost of $6.38 per share, for a total transaction of $319,000.00. Following the transaction, the insider directly owned 462,416 shares of the company’s stock, valued at approximately $2,950,214.08. The trade was a 12.12% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, CEO William P. Quinn sold 9,132 shares of the stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $3.24, for a total transaction of $29,587.68. Following the completion of the sale, the chief executive officer owned 25,384 shares in the company, valued at $82,244.16. This represents a 26.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 38,584 shares of company stock worth $128,361. Company insiders own 9.40% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Bolt Biotherapeutics stock. Nan Fung Group Holdings Ltd bought a new stake in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,000 shares of the company’s stock, valued at approximately $19,250. Bolt Biotherapeutics makes up 0.0% of Nan Fung Group Holdings Ltd’s holdings, making the stock its 25th biggest position. Nan Fung Group Holdings Ltd owned about 0.26% of Bolt Biotherapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments that activate the immune system to fight cancer. The company’s approach is designed to combine the targeting capabilities of antibodies with immune-stimulating components that recruit and activate innate immune cells within the tumor microenvironment. Bolt’s proprietary platform centers on Immune-Stimulating Antibody Conjugates, or ISACs. These investigational therapies are intended to bind to specific markers on tumor cells and deliver immune-stimulating payloads, potentially promoting tumor-cell destruction and generating a broader antitumor immune response.